Keyphrases
Netherlands
100%
Cost-effectiveness
67%
Dutch
44%
Quality-adjusted Life Years
29%
Cost-effectiveness Analysis
28%
Indonesia
22%
Vaccination
18%
Incremental Cost-effectiveness Ratio
17%
Budget Impact
17%
Systematic Literature Review
16%
Health-related Quality of Life
15%
Health Impact
15%
Economic Evaluation
15%
Multiple Myeloma
14%
Newborn Screening
14%
Multi-stakeholder
14%
Quality of Life
13%
Continuous Ambulatory Peritoneal Dialysis
12%
Hemodialysis
11%
Finnish Diabetes Risk Score
11%
Kidney Disease
11%
Standard of Care
11%
Chronic Kidney Disease
11%
Patient-Reported Outcomes Measurement Information System (PROMIS)
10%
Kidney
10%
COVID-19
10%
Patient Engagement
10%
Older Adults
10%
Diabetes
10%
Quadrivalent
10%
Willingness-to-pay Threshold
10%
Infectious Diseases
9%
Utility Score
9%
Reimbursement
9%
Cost Savings
9%
E-coaching
9%
Multiple Myeloma Patients
9%
Life-years Gained
9%
Societal Perspective
9%
Influenza
9%
Economic Impact
9%
Indonesian Population
9%
Cardiovascular Disease
8%
National Immunization Program
8%
Recently Diagnosed
8%
Patient-reported Outcomes
8%
Healthcare Professionals
8%
Patient-reported Experience Measures
8%
Kidney Disease Quality of life-36
8%
High Dose
8%
Medicine and Dentistry
Cost-Effectiveness Analysis
58%
Health Care Cost
44%
Quality Adjusted Life Year
27%
Quality of Life
26%
Drug Megadose
16%
Diabetes
15%
Cardiovascular System
15%
Systematic Review
14%
Multiple Myeloma
14%
Nephropathy
14%
Diseases
13%
Randomized Controlled Trial
11%
Lifespan
10%
Patient-Reported Outcome
9%
Cervical Cancer
8%
Cardiovascular Disease
8%
Influenza Vaccination
8%
CYP2C19
7%
Newborn Screening
7%
Spinal Muscular Atrophy
7%
Cost of Illness
7%
Meningococcal Disease
7%
Neisseria meningitidis
7%
Albuminuria
7%
Interstitial Lung Disease
7%
Nintedanib
7%
Respiratory Tract Infection
7%
Influenza Vaccine
7%
Dysglycemia
7%
Remote Patient Monitoring
7%
Non Small Cell Lung Cancer
7%
Rapid Diagnostic Test
7%
e-Health
7%
Drug Use
7%
Health Care
7%
Orphan Drug
7%
Wart Virus
7%
Patient Care
7%
Cross Sectional Study
7%
Primary Health Care
7%
Acute Heart Infarction
7%
Cell Therapy
7%
Gene Therapy
7%
Decision Making
7%
Health System
7%
Antiviral Drug
7%
Octreotide
7%
Lutetium
7%
Midgut
7%
Neuroendocrine Tumor
7%